Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Market price (% of par)
-
80.47%
-
Total 13F principal
-
$245,718,242
-
Principal change
-
-$8,928,179
-
Total reported market value
-
$198,931,644
-
Number of holders
-
29
-
Value change
-
-$16,150,064
-
Number of buys
-
14
-
Number of sells
-
17
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q3 2023
As of 30 Sep 2023,
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 was held by
29 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$245,718,242
in principal (par value) of the bond.
The largest 10 bondholders included
FRANKLIN RESOURCES INC, D. E. Shaw & Co., Inc., Graham Capital Management, L.P., AVIVA PLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, UBS OCONNOR LLC, Linden Advisors LP, CAPSTONE INVESTMENT ADVISORS, LLC, SSI INVESTMENT MANAGEMENT LLC, and CSS LLC/IL.
This page lists
29
institutional bondholders reporting positions
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.